Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
- PMID: 16011870
- DOI: 10.1016/j.pneurobio.2005.04.006
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Abstract
The blood-brain barrier (BBB) serves as a protective mechanism for the brain by preventing entry of potentially harmful substances from free access to the central nervous system (CNS). Tight junctions present between the brain microvessel endothelial cells form a diffusion barrier, which selectively excludes most blood-borne substances from entering the brain. Astrocytic end-feet tightly ensheath the vessel wall and appear to be critical for the induction and maintenance of the barrier properties of the brain capillary endothelial cells. Because of these properties, the BBB only allows entry of lipophilic compounds with low molecular weights by passive diffusion. However, many lipophilic drugs show negligible brain uptake. They are substrates for drug efflux transporters such as P-glycoprotein (Pgp), multidrug resistance proteins (MRPs) or organic anion transporting polypeptides (OATPs) that are expressed at brain capillary endothelial cells and/or astrocytic end-feet and are key elements of the molecular machinery that confers the special permeability properties to the BBB. The combined action of these carrier systems results in rapid efflux of xenobiotics from the CNS. The objective of this review is to summarize transporter characteristics (cellular localization, specificity, regulation, and potential inhibition) for drug efflux transport systems identified in the BBB and blood-cerebrospinal fluid (CSF) barrier. A variety of experimental approaches available to ascertain or predict the impact of efflux transport on brain access of therapeutic drugs also are described and critically discussed. The potential impact of efflux transport on the pharmacodynamics of agents acting in the CNS is illustrated. Furthermore, the current knowledge about drug efflux transporters as a major determinant of multidrug resistance of brain diseases such as epilepsy is reviewed. Finally, we summarize strategies for modulating or by-passing drug efflux transporters at the BBB as novel therapeutic approaches to drug-resistant brain diseases.
Similar articles
-
The blood-brain barrier: an overview: structure, regulation, and clinical implications.Neurobiol Dis. 2004 Jun;16(1):1-13. doi: 10.1016/j.nbd.2003.12.016. Neurobiol Dis. 2004. PMID: 15207256 Review.
-
Progress in brain penetration evaluation in drug discovery and development.J Pharmacol Exp Ther. 2008 May;325(2):349-56. doi: 10.1124/jpet.107.130294. Epub 2008 Jan 18. J Pharmacol Exp Ther. 2008. PMID: 18203948 Review.
-
Macromolecular drug transport into the brain using targeted therapy.J Neurochem. 2010 Apr;113(1):1-13. doi: 10.1111/j.1471-4159.2009.06544.x. Epub 2009 Dec 14. J Neurochem. 2010. PMID: 20015155 Review.
-
Structure and function of the blood-brain barrier.Neurobiol Dis. 2010 Jan;37(1):13-25. doi: 10.1016/j.nbd.2009.07.030. Epub 2009 Aug 5. Neurobiol Dis. 2010. PMID: 19664713 Review.
-
Transporter-mediated uptake into cellular compartments.Xenobiotica. 2007 Oct-Nov;37(10-11):1171-95. doi: 10.1080/00498250701570251. Xenobiotica. 2007. PMID: 17968742 Review.
Cited by
-
Viral Infection of the Central Nervous System Exacerbates Interleukin-10 Receptor Deficiency-Mediated Colitis in SJL Mice.PLoS One. 2016 Sep 9;11(9):e0161883. doi: 10.1371/journal.pone.0161883. eCollection 2016. PLoS One. 2016. PMID: 27611574 Free PMC article.
-
The blood-brain barrier in Alzheimer's disease.Neurobiol Dis. 2017 Nov;107:41-56. doi: 10.1016/j.nbd.2016.07.007. Epub 2016 Jul 15. Neurobiol Dis. 2017. PMID: 27425887 Free PMC article. Review.
-
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.J Nucl Med. 2009 Dec;50(12):1954-61. doi: 10.2967/jnumed.109.063289. Epub 2009 Nov 12. J Nucl Med. 2009. PMID: 19910428 Free PMC article. Clinical Trial.
-
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Expert Rev Mol Med. 2011 May 13;13:e17. doi: 10.1017/S1462399411001888. Expert Rev Mol Med. 2011. PMID: 21676290 Free PMC article. Review.
-
NanoART, neuroAIDS and CNS drug delivery.Nanomedicine (Lond). 2009 Jul;4(5):557-74. doi: 10.2217/nnm.09.38. Nanomedicine (Lond). 2009. PMID: 19572821 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous